CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome

Key Inclusion Criteria: * Adults, 18 years or older * Meet diagnostic criteria for Gorlin Syndrome * Willing to avoid application of a non-study topical medication to the face (prescription or over the counter) during the study. * Willing to forego treatment of BCCs with anything other than the study medication except when the Investigator believes that delay of treatment of a BCC potentially might compromise the health of the subject. During the trial, the only allowed form of BCC treatment is surgical. * Participant will be encouraged to use their preferred sunscreen with a sun protector factor (SPF) of at least 30 daily Key Exclusion Criteria: * Recently participated in a clinical trial evaluating an investigational product for the treatment of BCCs or Gorlin Syndrome within 3 months prior to to starting study medication. Participant can start the study screening period prior to completing the 3 month washout. * Recently used topical or systemic (oral) treatment that might interfere with the evaluation of the study medication.